Showing results (941-950 of 1,297) with videos related to
Sort By:
Pageof 130
American Journal of Preventive Medicine|January 1, 1990
Risk factors for cardiovascular disease in U.S. medical students: the Preventive Cardiology Academic Award Collaborative Data ProjectC B Eaton, D C Schaad, B Rybicki, et al.AJNR. American Journal of Neuroradiology|August 11, 2012
CT angiography for surgical planning in face transplantation candidatesS Soga, B Pomahac, N Wake, et al.Bone Marrow Transplantation|April 5, 2011
Etoposide plus G-CSF priming compared with G-CSF alone in patients with lymphoma improves mobilization without an increased risk of secondary myelodysplasia and leukemiaA Mahindra, B J Bolwell, L Rybicki, et al.Human Pathology|August 13, 2015
Risk factor analysis of recurrence in low-grade endometrial adenocarcinomaAndres A Roma, Lisa A Rybicki, Denise Barbuto, et al.Cancer|March 19, 2008
Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unitSnehal G Thakkar, Alex Z Fu, John W Sweetenham, et al.The Journal of Thoracic and Cardiovascular Surgery|July 2, 2002
Stage III non-small cell lung cancer and metachronous brain metastasesNader Moazami, Thomas W Rice, Lisa A Rybicki, et al.Journal of Virology|March 2, 2013
Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate modelGerald K Chege, Wendy A Burgers, Helen Stutz, et al.Radiation Oncology (London, England)|July 11, 2013
Oropharyngeal squamous cell carcinoma with known human papillomavirus status treated with definitive chemoradiotherapy: patterns of failure and toxicity outcomesTrevor J Bledsoe, Anisha R Noble, Grant K Hunter, et al.American Journal of Hematology|October 30, 2014
Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantationBetty K Hamilton, Lisa Rybicki, Robert Dean, et al.American Journal of Clinical Oncology|April 7, 2007
A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction: the impact of clinical heterogeneityDavid J Adelstein, Thomas W Rice, Lisa A Rybicki, et al.Pageof 130